These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7195468)

  • 1. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.
    Matsuo O; Rijken DC; Collen D
    Nature; 1981 Jun; 291(5816):590-1. PubMed ID: 7195468
    [No Abstract]   [Full Text] [Related]  

  • 2. When urokinase was gone: commentary on another year of thrombolysis without urokinase.
    Gates J; Hartnell GG
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):1-5. PubMed ID: 14709680
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombolytic effects of tissue-type and urokinase-type plasminogen activators in rabbits with experimental pulmonary thromboembolization.
    Rahman F
    Fukuoka Igaku Zasshi; 1990 Sep; 81(9):303-12. PubMed ID: 2125971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional thrombolysis in the ED for pulmonary embolism.
    Borsetti G; Morandi P; Bigoni M; Galeotti R; Sala S
    Am J Emerg Med; 2004 Oct; 22(6):501-2. PubMed ID: 15520957
    [No Abstract]   [Full Text] [Related]  

  • 5. Empirical thrombolysis in catastrophic pulmonary embolism.
    Kelly J
    J Accid Emerg Med; 1999 Jul; 16(4):314. PubMed ID: 10417954
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Friday afternoon pulmonary arteriography (FAPA): replacement by Friday afternoon urokinase (FAUK).
    Grollman JH
    Cardiovasc Intervent Radiol; 1998; 21(6):514. PubMed ID: 9853174
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombolysis with resolution of pulmonary hypertension in a heart transplant candidate.
    Lick S; Conti V
    Chest; 1999 Mar; 115(3):896-7. PubMed ID: 10084513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated?
    Dalen JE; Alpert JS; Hirsh J
    Arch Intern Med; 1997 Dec 8-22; 157(22):2550-6. PubMed ID: 9531222
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data].
    Zonzin P; Roncon L; Carraro M
    Ann Ital Med Int; 1996; 11(2):132-7. PubMed ID: 8974439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
    Gurewich V; Pannell R
    Semin Thromb Hemost; 1987 Apr; 13(2):146-51. PubMed ID: 3114882
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Emergency drug therapy of pulmonary thromboembolism].
    Shibuya Y; Tanaka H; Abe S
    Nihon Naika Gakkai Zasshi; 1995 Nov; 84(11):1798-803. PubMed ID: 8568376
    [No Abstract]   [Full Text] [Related]  

  • 14. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ; Páramo JA; Rocha E
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of right ventricular hypokinesis after thrombolysis in acute pulmonary embolism.
    Metz D; Nazeyrollas P; Mailier B; Jennesseaux C; Tasson S; Maes D; Elaerts J
    Am J Cardiol; 1996 Jun; 77(14):1252-4. PubMed ID: 8651110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thrombolytic therapy of thrombosis].
    Niiya K
    Nihon Naika Gakkai Zasshi; 1997 Jun; 86(6):972-80. PubMed ID: 9340366
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thrombolytic therapy for pulmonary thromboembolism].
    Pankov KS
    Klin Med (Mosk); 2004; 82(10):4-8. PubMed ID: 15584590
    [No Abstract]   [Full Text] [Related]  

  • 19. Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option.
    Krishnamurthy P; Martin CB; Kay HH; Diesner J; Friday RO; Weber CA; Droste S
    J Matern Fetal Med; 1999; 8(1):24-7. PubMed ID: 10052842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.